Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function

Venkata Parsa, Lance Heilbrun, Daryn Smith, Aastha Sethi, Ulka Vaishampayan

Research output: Contribution to journalArticle

Abstract

Purpose: Sorafenib is an oral Raf kinase inhibitor, approved for the treatment of advanced renal cancer. Clinical investigation of the safety and feasibility of sorafenib therapy in patients with impaired renal function was performed in this study. Materials and Methods: The protocol was approved by the Human Investigation Committee of Wayne State University. Medical records of patients with metastatic renal cancer at Wayne State University started on sorafenib between November 2005 to January 2007 were reviewed. Patients with a calculated creatinine clearance (CrCl) of 60 mL/min or less (chronic kidney disease stage 3 or greater per Kidney Disease Outcomes Quality Initiative guidelines) were deemed to have renal insufficiency. Results: A total of 32 patients who met the selection criteria were analyzed. Fourteen of 32 (44%) patients had renal insufficiency (range, 32-60 mL/min). Median age was 71 years in patients with CrCl < 60 mL/min and 54 years in those with > 60 mL/min. Incidence of diarrhea (57% vs. 33%) and hand-foot syndrome (86% vs. 56%) were higher in the renal-dysfunction group. Dose interruptions and dose reductions were noted in 57% and 43% of patients with renal dysfunction versus 28% and 22% in those without. No significant differences were noted in response rate, progression-free survival or overall survival. Conclusion: Renal insufficiency is frequently observed in patients with advanced renal cancer. Sorafenib therapy can be safely delivered in patients with mild and moderate renal dysfunction, and efficacy appears to be maintained.

Original languageEnglish (US)
JournalClinical Genitourinary Cancer
Volume7
Issue number2
DOIs
StatePublished - Jan 1 2009
Externally publishedYes

Fingerprint

Kidney Neoplasms
Kidney
Safety
Renal Insufficiency
Therapeutics
Creatinine
raf Kinases
Hand-Foot Syndrome
sorafenib
Kidney Diseases
Chronic Renal Insufficiency
Patient Selection
Disease-Free Survival
Medical Records
Diarrhea
Guidelines
Survival
Incidence

Keywords

  • Hand-foot syndrome
  • Hypertension
  • Renal dysfunction

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function. / Parsa, Venkata; Heilbrun, Lance; Smith, Daryn; Sethi, Aastha; Vaishampayan, Ulka.

In: Clinical Genitourinary Cancer, Vol. 7, No. 2, 01.01.2009.

Research output: Contribution to journalArticle

@article{dd41988922364d91b21234ee234fdf9e,
title = "Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function",
abstract = "Purpose: Sorafenib is an oral Raf kinase inhibitor, approved for the treatment of advanced renal cancer. Clinical investigation of the safety and feasibility of sorafenib therapy in patients with impaired renal function was performed in this study. Materials and Methods: The protocol was approved by the Human Investigation Committee of Wayne State University. Medical records of patients with metastatic renal cancer at Wayne State University started on sorafenib between November 2005 to January 2007 were reviewed. Patients with a calculated creatinine clearance (CrCl) of 60 mL/min or less (chronic kidney disease stage 3 or greater per Kidney Disease Outcomes Quality Initiative guidelines) were deemed to have renal insufficiency. Results: A total of 32 patients who met the selection criteria were analyzed. Fourteen of 32 (44{\%}) patients had renal insufficiency (range, 32-60 mL/min). Median age was 71 years in patients with CrCl < 60 mL/min and 54 years in those with > 60 mL/min. Incidence of diarrhea (57{\%} vs. 33{\%}) and hand-foot syndrome (86{\%} vs. 56{\%}) were higher in the renal-dysfunction group. Dose interruptions and dose reductions were noted in 57{\%} and 43{\%} of patients with renal dysfunction versus 28{\%} and 22{\%} in those without. No significant differences were noted in response rate, progression-free survival or overall survival. Conclusion: Renal insufficiency is frequently observed in patients with advanced renal cancer. Sorafenib therapy can be safely delivered in patients with mild and moderate renal dysfunction, and efficacy appears to be maintained.",
keywords = "Hand-foot syndrome, Hypertension, Renal dysfunction",
author = "Venkata Parsa and Lance Heilbrun and Daryn Smith and Aastha Sethi and Ulka Vaishampayan",
year = "2009",
month = "1",
day = "1",
doi = "10.3816/CGC.2009.n.015",
language = "English (US)",
volume = "7",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function

AU - Parsa, Venkata

AU - Heilbrun, Lance

AU - Smith, Daryn

AU - Sethi, Aastha

AU - Vaishampayan, Ulka

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Purpose: Sorafenib is an oral Raf kinase inhibitor, approved for the treatment of advanced renal cancer. Clinical investigation of the safety and feasibility of sorafenib therapy in patients with impaired renal function was performed in this study. Materials and Methods: The protocol was approved by the Human Investigation Committee of Wayne State University. Medical records of patients with metastatic renal cancer at Wayne State University started on sorafenib between November 2005 to January 2007 were reviewed. Patients with a calculated creatinine clearance (CrCl) of 60 mL/min or less (chronic kidney disease stage 3 or greater per Kidney Disease Outcomes Quality Initiative guidelines) were deemed to have renal insufficiency. Results: A total of 32 patients who met the selection criteria were analyzed. Fourteen of 32 (44%) patients had renal insufficiency (range, 32-60 mL/min). Median age was 71 years in patients with CrCl < 60 mL/min and 54 years in those with > 60 mL/min. Incidence of diarrhea (57% vs. 33%) and hand-foot syndrome (86% vs. 56%) were higher in the renal-dysfunction group. Dose interruptions and dose reductions were noted in 57% and 43% of patients with renal dysfunction versus 28% and 22% in those without. No significant differences were noted in response rate, progression-free survival or overall survival. Conclusion: Renal insufficiency is frequently observed in patients with advanced renal cancer. Sorafenib therapy can be safely delivered in patients with mild and moderate renal dysfunction, and efficacy appears to be maintained.

AB - Purpose: Sorafenib is an oral Raf kinase inhibitor, approved for the treatment of advanced renal cancer. Clinical investigation of the safety and feasibility of sorafenib therapy in patients with impaired renal function was performed in this study. Materials and Methods: The protocol was approved by the Human Investigation Committee of Wayne State University. Medical records of patients with metastatic renal cancer at Wayne State University started on sorafenib between November 2005 to January 2007 were reviewed. Patients with a calculated creatinine clearance (CrCl) of 60 mL/min or less (chronic kidney disease stage 3 or greater per Kidney Disease Outcomes Quality Initiative guidelines) were deemed to have renal insufficiency. Results: A total of 32 patients who met the selection criteria were analyzed. Fourteen of 32 (44%) patients had renal insufficiency (range, 32-60 mL/min). Median age was 71 years in patients with CrCl < 60 mL/min and 54 years in those with > 60 mL/min. Incidence of diarrhea (57% vs. 33%) and hand-foot syndrome (86% vs. 56%) were higher in the renal-dysfunction group. Dose interruptions and dose reductions were noted in 57% and 43% of patients with renal dysfunction versus 28% and 22% in those without. No significant differences were noted in response rate, progression-free survival or overall survival. Conclusion: Renal insufficiency is frequently observed in patients with advanced renal cancer. Sorafenib therapy can be safely delivered in patients with mild and moderate renal dysfunction, and efficacy appears to be maintained.

KW - Hand-foot syndrome

KW - Hypertension

KW - Renal dysfunction

UR - http://www.scopus.com/inward/record.url?scp=70449379934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449379934&partnerID=8YFLogxK

U2 - 10.3816/CGC.2009.n.015

DO - 10.3816/CGC.2009.n.015

M3 - Article

C2 - 19692316

AN - SCOPUS:70449379934

VL - 7

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 2

ER -